PremiumMarket NewsTop 3 Trending Stocks, According to Analysts – 4/11/2025 Cautious Outlook on Nurix Therapeutics Amid Promising Pipeline and Development Uncertainties management to meet with Stephens PremiumThe FlyNurix Therapeutics price target lowered to $35 from $36 at Stifel Nurix Therapeutics: Strong Financials and Strategic Collaborations Support ‘Buy’ Rating Promising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation PremiumRatingsNurix’s Strategic Licensing Deal and Promising Pipeline Catalysts Drive Buy Rating Nurix Therapeutics announces Sanofi exclusively licensed a program Nurix Therapeutics announces FDA ODD granted to bexobrutideg 
